Skip to main content

Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus Epitopes.

Publication ,  Journal Article
Kapingidza, B; Marston, DJ; Harris, C; Wrapp, D; Winters, K; Mielke, D; Xiaozhi, L; Yin, Q; Foulger, A; Parks, R; Barr, M; Newman, A; Vure, P ...
Published in: bioRxiv
September 17, 2023

Immune responses to SARS-CoV-2 primarily target the receptor binding domain of the spike protein, which continually mutates to escape acquired immunity. Other regions in the spike S2 subunit, such as the stem helix and the segment encompassing residues 815-823 adjacent to the fusion peptide, are highly conserved across sarbecoviruses and are recognized by broadly reactive antibodies, providing hope that vaccines targeting these epitopes could offer protection against both current and emergent viruses. Here we employed computational modeling to design scaffolded immunogens that display the spike 815-823 peptide and the stem helix epitopes without the distracting and immunodominant RBD. These engineered proteins bound with high affinity and specificity to the mature and germline versions of previously identified broadly protective human antibodies. Epitope scaffolds interacted with both sera and isolated monoclonal antibodies with broadly reactivity from individuals with pre-existing SARS-CoV-2 immunity. When used as immunogens, epitope scaffolds elicited sera with broad betacoronavirus reactivity and protected as "boosts" against live virus challenge in mice, illustrating their potential as components of a future pancoronavirus vaccine.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

bioRxiv

DOI

EISSN

2692-8205

Publication Date

September 17, 2023

Location

United States
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kapingidza, B., Marston, D. J., Harris, C., Wrapp, D., Winters, K., Mielke, D., … Azoitei, M. L. (2023). Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus Epitopes. BioRxiv. https://doi.org/10.1101/2023.02.27.530277
Kapingidza, Brenda, Daniel J. Marston, Caitlin Harris, Daniel Wrapp, Kaitlyn Winters, Dieter Mielke, Lu Xiaozhi, et al. “Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus Epitopes.BioRxiv, September 17, 2023. https://doi.org/10.1101/2023.02.27.530277.
Kapingidza B, Marston DJ, Harris C, Wrapp D, Winters K, Mielke D, et al. Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus Epitopes. bioRxiv. 2023 Sep 17;
Kapingidza, Brenda, et al. “Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus Epitopes.BioRxiv, Sept. 2023. Pubmed, doi:10.1101/2023.02.27.530277.
Kapingidza B, Marston DJ, Harris C, Wrapp D, Winters K, Mielke D, Xiaozhi L, Yin Q, Foulger A, Parks R, Barr M, Newman A, Schäfer A, Eaton A, Flores JM, Harner A, Cantazaro NJ, Mallory ML, Mattocks MD, Beverly C, Rhodes B, Mansouri K, Itallie EV, Vure P, Manness B, Keyes T, Stanfield-Oakley S, Woods CW, Petzold EA, Walter EB, Wiehe K, Edwards RJ, Montefiori D, Ferrari G, Baric R, Cain DW, Saunders KO, Haynes BF, Azoitei ML. Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus Epitopes. bioRxiv. 2023 Sep 17;

Published In

bioRxiv

DOI

EISSN

2692-8205

Publication Date

September 17, 2023

Location

United States